Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. Arena owns a patent portfolio covering a broad array of internally discovered, oral GPR119 agonists, including next generation compounds that were not part of the collaboration.

The Phase 1 program evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597, and included single and multi-ascending studies in healthy volunteers and in subjects with type 2 diabetes. APD597 was well tolerated and showed dose-proportional pharmacokinetics with a half-life of six to seven hours in solution and approximately 13 hours in suspension in healthy volunteers. The Phase 1 program also provided evidence for incretin stimulation (GLP-1, GIP and PYY) and reductions in post-meal glucose increases with APD597 treatment in both overweight and obese non-diabetic volunteers and in subjects with type 2 diabetes. In general, reductions in post-meal glucose increases were greater with APD597 in combination with sitagliptin, a DPP-4 inhibitor, compared to sitagliptin alone.

"Results of the Phase 1 program suggest that APD597 may have utility both alone and in combination with a DPP-4 inhibitor for the treatment of type 2 diabetes," said Jack Lief, Arena's President and Chief Executive Officer. "With our existing GPR119 patent portfolio, internally discovered next generation compounds a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014   Plexus Information Systems, Inc. ... Information Management Systems (AIMS), announced a partnership with ... wholly owned subsidiary of Quality Systems, Inc. and ... connectivity solutions.  Logo - ... This partnership extends the NextGen Healthcare ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014  Columbia ... that its subsidiary, Molecular Profiles Ltd., is set to ... annual CPhI/ICSE Worldwide event in Paris ... the rapid development of both standard and complex drug ... which incorporates the company,s existing formulation and analytical development ...
(Date:10/1/2014)... ANTWERP, Belgium and NEW YORK , ... global Contract Research Organization (CRO) and service provider for the medical ... the opening of offices in New York City ... New York City is strategically centered in one of ... the East Coast", said Philippe Kassab , President at genae ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2
... Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed ... was Well Tolerated When Given With Standard Platelet TherapyKENILWORTH, ... (NYSE: SGP ) Phase II trial of ... were published today in The Lancet and ...
... uses quantitative imaging endpoints from MRI analysesROCHESTER, N.Y., ... VSCP ), a leading provider of quantitative imaging ... a Canadian medical device company based in Laval, ... Canadian-European pivotal clinical trial for its cartilage repair ...
Cached Medicine Technology:Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 2VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 3
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product manufacturer and retailer. ... the global customers in the past few years. Now, ... items. All its online workers are professional and patient; ... The company has recently added a new assortment of ... company’s marketing specialist has announced that all these brand ...
(Date:10/2/2014)... (HealthDay News) -- Children with autism are more sedentary ... of being more active, a small study suggests. ... children, some with autism and some without. Children with ... physical activity and 70 more minutes each day sitting ... autism scored lower on strength, but had similar body-mass ...
(Date:10/2/2014)... By Dennis Thompson ... -- Forty-two states and the District of Columbia now have ... severe respiratory illness that has been infecting children since ... infected with the virus have died in recent weeks, but ... virus played in those deaths, officials said. Health officials ...
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... people to keep their "eyes on the prize" may ... walking, staying focused on a specific target ahead can ... people walk there faster, psychology researchers have found. Their ... around the environment naturally, offers a new strategy to ... interested in exercise if physical activity seems daunting, which ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... 1 /PRNewswire-Asia/ -- Linkwell Corporation,(OTC Bulletin Board: LWLL), a ... put forward its worries about,the trend of the misunderstanding ... "Antisepsis is one of the most ... will work best when used with the H1N1 vaccine,",said ...
... , GENEVA, Sept. 1 Selexis SA ... they have entered into a research services agreement whereby ... CHO-based production cell lines using their novel platform named ... of production cell lines concomitant with the selection of ...
... in half for Italian study patients , TUESDAY, Sept.1 (HealthDay ... to develop blood clots than other people, but now a ... in half. , Besides posing a significant risk of ... especially difficult to treat in cancer patients and can lead ...
... , , , ... leaders, health plan executives and experts from Health Integrated will share perspectives ... during a provocative two-day program at The Westin Michigan Avenue in Chicago, ... http://www.newscom.com/cgi-bin/prnh/20090709/FL43703LOGO ) , , "Wins of ...
... , , COLUMBUS, Ga., ... for Childhood Cancer Awareness Month by kicking off a new integrated fundraising ... Service of Children,s Healthcare of Atlanta . Childhood cancer is the ... of 15. Through improved research and treatments, childhood cancer survival rates have ...
... KENILWORTH, N.J., Sept. 1 Schering-Plough Corporation (NYSE: ... only 12-hour allergy medicine found in the allergy aisle. New CLARITIN ... worst indoor and outdoor allergy symptoms. The product is available ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090901/NY68186 ) , ...
Cached Medicine News:Health News:Which is the Real Terminator of H1N1 Disease, the Antisepsis or the Vaccine? 2Health News:Which is the Real Terminator of H1N1 Disease, the Antisepsis or the Vaccine? 3Health News:Selexis and NKT Therapeutics Enter Into Research Services Agreement 2Health News:Blood Thinner May Prevent Chemo-Related Clots 2Health News:Health Plan Executives to Share Winning Strategies in the Age of Reform During Health Integrated Forum 2Health News:Aflac Announces Support for Childhood Cancer Awareness Month 2Health News:Aflac Announces Support for Childhood Cancer Awareness Month 3Health News:Aflac Announces Support for Childhood Cancer Awareness Month 4Health News:Aflac Announces Support for Childhood Cancer Awareness Month 5Health News:New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day 2Health News:New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day 3
... the first skull pin to utilize cutting edges instead ... its way into bone the Hifix pin drills a ... improved initial fixation over standard skull pins. The Hifix ... Hifix pins and in the bremer 3D halo crown. ...
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Endoscopes...
Patented* Design for Endoscopic Shunt Placement. Designed to pass through standard shunt ventricular catheters for optically guided placement....
Medicine Products: